Researchers identified a single heterozygous nucleotide variant that confers resistance to venetoclax, and it's a mutation that may be detected years before clinical relapse occurs.
from Latest articles from Cancer Therapy Advisor Hematologic Cancers https://ift.tt/2EfsL7u
from Latest articles from Cancer Therapy Advisor Hematologic Cancers https://ift.tt/2EfsL7u